NCT04221438 2026-03-12
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
Phase 2 Terminated
Clinical Trials
14 trialsNCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT04657991 2026-03-02
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
Phase 3 Active not recruiting
NCT04741997 2026-03-02
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT03543969 2026-02-05
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT02910700 2025-12-17
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06194929 2025-12-03
DETERMINE
University of Utah
Phase 1/2 Recruiting
NCT06887088 2025-10-01
ENCEFALO
Grupo Español Multidisciplinar de Melanoma
Phase 2 Recruiting
NCT07022457 2025-08-03
UK-EnBiRiM
Pierre Fabre Ltd
Recruiting
NCT03235245 2025-08-01
EBIN
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT07092410 2025-07-29
SuRage-EB
SRH Wald-Klinikum Gera GmbH
Phase 4 Not yet recruiting
NCT05304546 2025-07-22
MK3475-C01
Sheba Medical Center
Phase 2 Completed
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed